UniQure PE Ratio 2013-2021 | QURE

Current and historical p/e ratio for UniQure (QURE) from 2013 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. UniQure PE ratio as of October 26, 2021 is 4.17.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

UniQure PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 29.06 4.55
2021-06-30 30.80 $6.38 4.83
2021-03-31 33.69 $-3.09 0.00
2020-12-31 36.13 $-2.81 0.00
2020-09-30 36.83 $-3.77 0.00
2020-06-30 45.06 $-3.14 0.00
2020-03-31 47.45 $-3.01 0.00
2019-12-31 71.66 $-3.12 0.00
2019-09-30 39.36 $-2.74 0.00
2019-06-30 78.15 $-2.75 0.00
2019-03-31 59.65 $-2.49 0.00
2018-12-31 28.82 $-2.34 0.00
2018-09-30 36.39 $-2.66 0.00
2018-06-30 37.80 $-2.47 0.00
2018-03-31 23.50 $-2.73 0.00
2017-12-31 19.59 $-2.94 0.00
2017-09-30 9.60 $-2.61 0.00
2017-06-30 6.19 $-2.81 0.00
2017-03-31 5.78 $-2.96 0.00
2016-12-31 5.60 $-3.08 0.00
2016-09-30 7.65 $-3.14 0.00
2016-06-30 7.37 $-3.74 0.00
2016-03-31 11.88 $-3.72 0.00
2015-12-31 16.54 $-3.55 0.00
2015-09-30 20.45 $-2.91 0.00
2015-06-30 27.00 $-2.34 0.00
2015-03-31 24.32 $-2.05 0.00
2014-12-31 14.81 $-2.01 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.312B $0.038B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86